Create personalized user journeys with Omnichannel Marketing as a Service.
Empower your marketing operations with AI and Data.
Adopt a future-proof holistic approach to content strategy.
Leverage a suite of professional services for pharma and life sciences.
Develop and enable adaptable pharma and life sciences marketing content.
Enable format-free marketing with content management platform.
End-to-end platform for content validation and sales force readiness.
AI-powered congress engagement coordinator.
Discover our story, values, and how we're making a positive impact
Explore the heart of our organization and meet the visionary minds
Join the Viseven team and grow your career with us
The Viseven team is about respect, diversity, comfortable working conditions, and equal opportunities for everyone. We explore, evolve, and adapt – together.
“Are you unbiased?” It’s a fair question after reading a title like this.
The honest answer is not completely. We built eWizard, an AI-powered content supply chain platform, so we naturally have firsthand experience with the challenges pharma teams face and the capabilities that help solve them.
That said, this article is not intended to be a product pitch.
Our goal is to give you enough context to make a genuinely informed decision that fits your needs, whether or not that turns out to be eWizard.
Why is choosing a content authoring platform such a big deal? At the end of the day, why not just let your content and creative teams do the job the way they always did, even if it is slower?
In fact, content velocity is only a part of a puzzle. Slower production cycles and delayed releases translate into missed engagement opportunities, a challenge that becomes especially palpable when engaging HCPs whose clinical opinions carry much weight in patient care decisions.
Commercial teams are being pushed to launch faster. HCP attention is limited too, most of them only actively engage with no more than three brands. Pharma marketers are trying to shorten production cycles to make it into that small shortlist.
The problem is that the MLR review process alone takes about 24 days on average, making the content supply chain slow and cumbersome. If there’s a missing claim, an outdated reference, or something gets published in the wrong country, it triggers revisions, which pushes everything back even more.
A single campaign for, say, a new oncology drug may require several unique eDetailers for reps, HCP emails, CLM assets, landing pages, print materials, and all of it has to be done in multiple languages and approved by regulatory teams across different markets. And as a cherry on top, more than half of pharma marketers need new materials every two months.
That’s why a lot of teams are turning to AI to speed up content production. But they’re often cautious with generic tools, and honestly, for a good reason. A 2026 study showed that large language models’ medical information outputs can be wrong or even unsafe in up to 43% of cases. In pharma, that can turn into compliance problems, extra review cycles, delays, and in the worst case, even regulatory or patient safety risks.
The platforms that win in this space are pharma-specific and cover the full omnichannel supply chain, from brand planning and briefing all the way through content production, approval, and distribution.
The right fit will depend on your organization’s size, current needs, and the specific problems you’re trying to solve.
A single product rollout can span dozens of markets, multiple regulatory environments, channel-specific content requirements, and cross-functional teams working across time zones. Campaign managers need to keep multiple balls in the air, like asset dependencies, brand consistency checks, and market-specific scheduling.
As generic project management tools were never designed for these specific demands, the industry has been moving toward platforms that consolidate planning, execution, and tracking in one place.
eWizard’s Campaign Set Initiative (CSI) and Planner feature set, including Gantt charts, asset dependency tracking, Brand/Journey widgets, and milestone scheduling, is built for multi-market, multi-channel pharma launches. Internal benchmarks show time savings of around 15 hours per month in campaign coordination.
Teams often judge the platform by the number of integrations. However, integration depth is equally important. The ability to connect with Veeva Vault, SFMC, and CRM systems and to maintain those connections as external platforms evolve is a key requirement today.
So, when evaluating a platform vendor, don’t stop at asking whether it integrates with your existing systems. Understand how the integration works, what data is exchanged, how updates are managed, and ask for evidence that it performs reliably in real-world scenarios.
With eWizard, authoring-to-Veeva as a single continuous process where metadata, version records, and compliance documentation flowing automatically at every stage. It follows NEXT and TAGS standards, which helps it integrate easily with other pharma-focused tools.
Our experience shows that most content creation happens at the local level, with nearly 80% of assets being created from scratch.
Many brands invest in modular content to boost reuse but struggle to achieve the promised benefits. They are told that modular content should be channel-agnostic and design-free. This often results in repositories full of modules that are difficult to assemble into assets.
Content and design are never completely separate. The moment a module is used in an email, website, eDetailer, or another channel, it needs a design context to be displayed correctly.
That’s why it’s important to choose a platform that can automatically apply design based on a module’s structure. Standardized content blocks should define the logic needed to render content consistently across channels and formats. This way, design becomes part of the rules governing how content is assembled and presented.
Based on our experience, organizations that establish this foundation can reduce time to market by up to 30%, increase content reuse by more than 50%, and produce up to three times more assets compared to their previous content operations.
The industry average for an MLR review cycle is around 24 days, which creates significant delays as marketing teams often need to launch new content every few months.
Automated validation catches compliance issues before content reaches reviewers. As teams improve templates and claim libraries based on review feedback, recurring errors become less common, reducing risk and rework across all content.
eVa, eWizard’s AI agent, helps speed up the MLR process by identifying potential compliance issues at both global and local levels, suggesting improvements, and estimating the likelihood of approval before formal review begins. According to internal benchmarks, this can reduce MLR review timelines to approximately 17 days (about 30% compared to industry averages).
When AI is approached as a tactic, teams simply add disconnected tools like claims checkers, content generators, and tagging platforms. The stats show that nearly 60% of pharma brands still fail to fully embed AI across the organization.
But when AI is treated as part of a broader strategy, it becomes a connected content supply chain that drives higher engagement at lower cost.
eWizard’s AI agent for life sciences teams, helps generate content from compliant DAM assets, speed up MLR reviews, automatically tags content, and makes it easy to reuse approved pieces across different markets and campaigns. Unlike general AI tools, it works within strict pharma compliance rules.
Several questions should guide your decision-making:
Organizations operating across multiple markets and regulatory frameworks, including the U.S. Food and Drug Administration, European Medicines Agency, and regional health authorities, often require advanced capabilities to support complex MLR processes, audit readiness, and local compliance requirements. In these cases, a pharma-focused platform can help improve MLR review workflows, maintain content traceability, manage approved claims and references, and ensure compliance remains embedded throughout the content supply chain.
The content platform should fit into your existing ecosystem to ensure free data flow, minimizing delays and boosting personalization. Before making a decision, assess how the platform integrates with the systems your teams rely on every day. For example, if Veeva Systems is central to your operations through CRM, Vault, or PromoMats, prioritize platforms with native Veeva integrations.
Teams producing high volumes of diverse content formats, such as eDetailers, emails, websites, banners, videos, and print materials, benefit from platforms with broad authoring capabilities that support multiple channels and content types from a single environment.
Content authoring tools vary significantly in both capabilities and pricing. Some are enterprise-grade solutions designed for global organizations with complex workflows and correspondingly large budgets. Others cater to mid-sized teams with more moderate requirements and investment levels. There are also cost-effective tools that perform well within specific niches but may lack the functionality needed to support an end-to-end content supply chain.
eWizard, for example, is the natural choice for large pharma teams running complex, multi-market HCP campaigns. It is not positioned for small teams or budget-constrained organizations, and the initial setup requires investment in training and integration configuration.
The platforms that were designed for life sciences perform better on compliance, integration depth, and time-to-market. The investment in a pharma-focused solution pays off in reduced regulatory risk, faster MLR cycles, and scalable HCP engagement.
General marketing platforms may play supporting roles in a broader marketing stack. But pharma organizations that rely on them as primary HCP content platforms are accepting regulatory risk and operational inefficiency.
Book a free demo to explore the platform firsthand.
Content authoring tools are software platforms that enable teams to create, manage, and publish content across multiple formats and channels. They typically offer structured templates, version control, and asset management. In the pharma space, these tools range from pharma-specific platforms to general-purpose solutions adapted for pharma use, as well as tools with limited relevance to regulated content workflows.
Most physicians actively engage with no more than three brands, so missing a launch window means handing that opportunity to a competitor. A single campaign can require eDetailers, emails, CLM assets, and print materials across multiple markets and languages, all needing regulatory sign-off. MLR review alone averages 24 days, and one missing claim or outdated reference triggers revisions that push everything back. With most pharma marketers needing fresh materials every two months, the right platform becomes a commercial necessity.
Brands should pay attention to functionalities like modular content creation, MLR review scoring, AI features, campaign planning, modular content, and integration depth.
As AI reshapes a content supply chain, manual-heavy tools are losing relevance. Platforms powered by AI now automate compliance checks, speed up content creation, increase reuse, and support personalization at scale. By contrast, traditional manual tools introduce delays, reduce agility, and make it harder for brands to engage HCPs in time.
Medical, legal, and regulatory reviewers remain essential for validating claims, verifying references, and catching nuances that AI misses. Human input is equally important for building strategy and creating engaging ideas that keep HCP engaged and invested, rather than recycling the same content only.
